Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma

University Hospital Carl Gustav Carus9 enrolled

Overview

Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Multiple Myeloma Plasmocytoma

Interventions

autologous idiotype-protein pulsed dendritic cellsBIOLOGICAL

Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * multiple myeloma * stage I (Salmon \& Durie) * no cytoreductive pre-treatment Exclusion Criteria: * myeloma stages II-III * asecretory disease

Locations (1)

University Hospital Dresden

Dresden, Germany

Outcomes

Primary Outcomes

Specific T-cell proliferation/cytokine secretion

Secondary Outcomes

number of T cells

Time frame: pre and post vaccination

monoclonal protein

Time frame: pre and post vaccination

plasmacells in bone marrow

Time frame: pre and post vaccination

vital signs

Time frame: pre and post vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.